| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 148 | 2022 | 756 | 15.220 |
Why?
|
| Lupus Nephritis | 43 | 2021 | 193 | 5.350 |
Why?
|
| Genetic Predisposition to Disease | 66 | 2022 | 786 | 3.450 |
Why?
|
| Estrogen Receptor alpha | 9 | 2022 | 65 | 3.170 |
Why?
|
| Autoantibodies | 52 | 2022 | 434 | 3.060 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 12 | 2022 | 63 | 2.800 |
Why?
|
| Antibodies, Antinuclear | 40 | 2022 | 171 | 2.440 |
Why?
|
| Polymorphism, Single Nucleotide | 54 | 2021 | 627 | 2.420 |
Why?
|
| Mice, Inbred MRL lpr | 40 | 2022 | 118 | 2.390 |
Why?
|
| Mice | 125 | 2022 | 8474 | 2.340 |
Why?
|
| Autoimmune Diseases | 20 | 2022 | 186 | 2.220 |
Why?
|
| Kidney | 33 | 2021 | 945 | 1.840 |
Why?
|
| Animals | 137 | 2022 | 20881 | 1.780 |
Why?
|
| Nitric Oxide | 17 | 2013 | 382 | 1.630 |
Why?
|
| Autoimmunity | 14 | 2022 | 118 | 1.590 |
Why?
|
| B-Lymphocytes | 21 | 2018 | 329 | 1.570 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 13 | 2021 | 106 | 1.490 |
Why?
|
| Nitric Oxide Synthase | 12 | 2006 | 163 | 1.470 |
Why?
|
| Female | 167 | 2023 | 38074 | 1.470 |
Why?
|
| DNA, Bacterial | 16 | 1998 | 150 | 1.370 |
Why?
|
| Kidney Glomerulus | 11 | 2014 | 155 | 1.360 |
Why?
|
| Mice, Knockout | 32 | 2018 | 1692 | 1.330 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2022 | 245 | 1.300 |
Why?
|
| Haplotypes | 32 | 2020 | 174 | 1.200 |
Why?
|
| Dendritic Cells | 9 | 2022 | 201 | 1.160 |
Why?
|
| Glomerulonephritis | 12 | 2012 | 77 | 1.150 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 4 | 2012 | 201 | 1.120 |
Why?
|
| T-Lymphocytes | 16 | 2020 | 597 | 1.090 |
Why?
|
| Polymorphism, Genetic | 8 | 2018 | 301 | 1.070 |
Why?
|
| Humans | 176 | 2023 | 68618 | 1.050 |
Why?
|
| Spleen | 23 | 2018 | 301 | 1.040 |
Why?
|
| Proteinuria | 17 | 2021 | 136 | 1.040 |
Why?
|
| Inflammation Mediators | 10 | 2021 | 244 | 1.010 |
Why?
|
| Complement Pathway, Alternative | 10 | 2011 | 69 | 1.000 |
Why?
|
| Case-Control Studies | 37 | 2019 | 1553 | 0.970 |
Why?
|
| Male | 127 | 2022 | 37321 | 0.960 |
Why?
|
| Mice, Inbred BALB C | 25 | 2012 | 532 | 0.960 |
Why?
|
| Genotype | 36 | 2021 | 786 | 0.930 |
Why?
|
| Alleles | 26 | 2020 | 386 | 0.910 |
Why?
|
| Transcription Factors | 11 | 2014 | 753 | 0.900 |
Why?
|
| Disease Models, Animal | 29 | 2021 | 2550 | 0.890 |
Why?
|
| Reactive Oxygen Species | 5 | 2017 | 499 | 0.890 |
Why?
|
| Nitric Oxide Synthase Type III | 3 | 2013 | 102 | 0.880 |
Why?
|
| Mice, Inbred C57BL | 34 | 2022 | 2791 | 0.870 |
Why?
|
| Immunoglobulin G | 26 | 2022 | 481 | 0.850 |
Why?
|
| Rheumatic Diseases | 2 | 2022 | 35 | 0.840 |
Why?
|
| Arthritis, Rheumatoid | 11 | 2020 | 157 | 0.840 |
Why?
|
| DNA | 21 | 2022 | 597 | 0.830 |
Why?
|
| Promoter Regions, Genetic | 14 | 2020 | 615 | 0.820 |
Why?
|
| DNA-Binding Proteins | 13 | 2014 | 700 | 0.820 |
Why?
|
| Kidney Diseases | 10 | 2021 | 307 | 0.810 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 6 | 2005 | 66 | 0.770 |
Why?
|
| NADPH Oxidases | 3 | 2021 | 80 | 0.760 |
Why?
|
| Antigen-Antibody Complex | 9 | 2014 | 175 | 0.760 |
Why?
|
| Complement C3 | 13 | 2018 | 101 | 0.750 |
Why?
|
| Gene Expression Regulation | 17 | 2020 | 1293 | 0.720 |
Why?
|
| Monocytes | 6 | 2023 | 210 | 0.710 |
Why?
|
| Immunoglobulin Variable Region | 6 | 2000 | 40 | 0.710 |
Why?
|
| Trichloroethylene | 3 | 2009 | 41 | 0.700 |
Why?
|
| Glycosphingolipids | 1 | 2020 | 51 | 0.690 |
Why?
|
| Adult | 61 | 2022 | 21403 | 0.690 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 163 | 0.690 |
Why?
|
| Immunity | 3 | 2011 | 67 | 0.690 |
Why?
|
| Arthritis | 7 | 2010 | 53 | 0.670 |
Why?
|
| Chemokine CCL2 | 4 | 2014 | 101 | 0.670 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2019 | 626 | 0.650 |
Why?
|
| Macrophages | 8 | 2021 | 647 | 0.640 |
Why?
|
| Glomerular Mesangium | 5 | 2006 | 53 | 0.620 |
Why?
|
| Lymphocytes | 6 | 2013 | 228 | 0.620 |
Why?
|
| Up-Regulation | 11 | 2022 | 682 | 0.620 |
Why?
|
| Disease Susceptibility | 2 | 2018 | 179 | 0.620 |
Why?
|
| Estrogens | 5 | 2022 | 173 | 0.620 |
Why?
|
| Proto-Oncogene Proteins c-ets | 3 | 2007 | 79 | 0.610 |
Why?
|
| Mesangial Cells | 3 | 2014 | 37 | 0.610 |
Why?
|
| Toll-Like Receptors | 3 | 2022 | 56 | 0.590 |
Why?
|
| Nitrates | 7 | 2011 | 61 | 0.590 |
Why?
|
| Cell Proliferation | 9 | 2019 | 1174 | 0.580 |
Why?
|
| Reactive Nitrogen Species | 2 | 2007 | 32 | 0.570 |
Why?
|
| Estrogen Receptor beta | 3 | 2017 | 19 | 0.570 |
Why?
|
| Cells, Cultured | 17 | 2018 | 2673 | 0.560 |
Why?
|
| Mice, Inbred NZB | 11 | 2012 | 37 | 0.550 |
Why?
|
| Decision Making | 1 | 2020 | 410 | 0.550 |
Why?
|
| Nitrites | 6 | 2011 | 53 | 0.540 |
Why?
|
| PPAR gamma | 3 | 2005 | 95 | 0.540 |
Why?
|
| Synovial Membrane | 4 | 2011 | 23 | 0.540 |
Why?
|
| Phenotype | 15 | 2020 | 947 | 0.540 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 378 | 0.540 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2022 | 124 | 0.530 |
Why?
|
| Autoantigens | 3 | 2006 | 91 | 0.520 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 445 | 0.510 |
Why?
|
| Tyrosine | 4 | 2013 | 196 | 0.510 |
Why?
|
| Arthritis, Experimental | 2 | 2012 | 38 | 0.510 |
Why?
|
| Microbiota | 3 | 2022 | 80 | 0.500 |
Why?
|
| Superoxides | 2 | 2013 | 70 | 0.490 |
Why?
|
| Cytokines | 8 | 2021 | 866 | 0.490 |
Why?
|
| Sex Characteristics | 3 | 2014 | 295 | 0.480 |
Why?
|
| Membrane Proteins | 8 | 2018 | 617 | 0.480 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 248 | 0.480 |
Why?
|
| Genome-Wide Association Study | 11 | 2018 | 240 | 0.470 |
Why?
|
| Base Sequence | 15 | 2012 | 1015 | 0.470 |
Why?
|
| Interferon Type I | 4 | 2022 | 32 | 0.460 |
Why?
|
| Middle Aged | 48 | 2022 | 21147 | 0.460 |
Why?
|
| Risk Factors | 29 | 2019 | 5731 | 0.460 |
Why?
|
| Kidney Cortex | 1 | 2013 | 19 | 0.460 |
Why?
|
| Immunosuppressive Agents | 6 | 2014 | 514 | 0.460 |
Why?
|
| Gene Expression | 12 | 2020 | 770 | 0.450 |
Why?
|
| Genetic Loci | 6 | 2013 | 59 | 0.450 |
Why?
|
| Enzyme Inhibitors | 6 | 2013 | 659 | 0.440 |
Why?
|
| Immunization | 7 | 1998 | 86 | 0.440 |
Why?
|
| Lipopolysaccharides | 12 | 2019 | 455 | 0.440 |
Why?
|
| Prostaglandin D2 | 4 | 2003 | 21 | 0.430 |
Why?
|
| Signal Transduction | 7 | 2018 | 2689 | 0.430 |
Why?
|
| Interleukin-10 | 5 | 2022 | 144 | 0.420 |
Why?
|
| Inflammation | 7 | 2022 | 1030 | 0.420 |
Why?
|
| Nuclear Proteins | 4 | 2011 | 271 | 0.420 |
Why?
|
| Joints | 2 | 2010 | 30 | 0.420 |
Why?
|
| Complement System Proteins | 4 | 2013 | 135 | 0.420 |
Why?
|
| Occupational Exposure | 4 | 2008 | 122 | 0.410 |
Why?
|
| Biomarkers | 5 | 2020 | 1593 | 0.410 |
Why?
|
| Nitric Oxide Synthase Type II | 9 | 2008 | 201 | 0.410 |
Why?
|
| Interleukin-6 | 5 | 2017 | 330 | 0.410 |
Why?
|
| Molecular Sequence Data | 13 | 2012 | 1447 | 0.410 |
Why?
|
| DNA Nucleotidylexotransferase | 2 | 2003 | 5 | 0.400 |
Why?
|
| Antibody Specificity | 6 | 2012 | 98 | 0.400 |
Why?
|
| Cognition Disorders | 1 | 2014 | 342 | 0.390 |
Why?
|
| Complement Factor B | 5 | 2007 | 19 | 0.390 |
Why?
|
| Apoptosis | 6 | 2017 | 1641 | 0.390 |
Why?
|
| Vitamin D Deficiency | 3 | 2016 | 292 | 0.390 |
Why?
|
| Down-Regulation | 5 | 2020 | 447 | 0.390 |
Why?
|
| Transforming Growth Factor beta | 5 | 2022 | 384 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 9 | 2007 | 511 | 0.380 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2014 | 226 | 0.380 |
Why?
|
| Adolescent | 26 | 2022 | 8912 | 0.380 |
Why?
|
| Thromboxane A2 | 1 | 2011 | 88 | 0.370 |
Why?
|
| Flow Cytometry | 8 | 2014 | 489 | 0.370 |
Why?
|
| STAT1 Transcription Factor | 4 | 2018 | 35 | 0.370 |
Why?
|
| DNA, Single-Stranded | 13 | 1997 | 41 | 0.370 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2011 | 46 | 0.370 |
Why?
|
| South Carolina | 9 | 2020 | 2752 | 0.370 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2022 | 122 | 0.370 |
Why?
|
| Synovitis | 1 | 2010 | 8 | 0.370 |
Why?
|
| Hydroxamic Acids | 3 | 2008 | 84 | 0.360 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 142 | 0.360 |
Why?
|
| Employment | 2 | 2009 | 154 | 0.360 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 15 | 2019 | 507 | 0.350 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2018 | 214 | 0.350 |
Why?
|
| Sulfonamides | 1 | 2011 | 141 | 0.350 |
Why?
|
| Thiazolidinediones | 5 | 2005 | 77 | 0.340 |
Why?
|
| Interferon Regulatory Factors | 4 | 2014 | 24 | 0.340 |
Why?
|
| Pyrazoles | 1 | 2011 | 190 | 0.340 |
Why?
|
| Transcription, Genetic | 3 | 2014 | 562 | 0.340 |
Why?
|
| Immunoglobulin Heavy Chains | 4 | 2004 | 72 | 0.340 |
Why?
|
| RNA, Messenger | 9 | 2022 | 1664 | 0.340 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 3 | 2021 | 14 | 0.330 |
Why?
|
| Linkage Disequilibrium | 12 | 2016 | 91 | 0.330 |
Why?
|
| H-2 Antigens | 2 | 2006 | 7 | 0.330 |
Why?
|
| Umbilical Cord | 3 | 2022 | 19 | 0.330 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2008 | 116 | 0.330 |
Why?
|
| Child | 14 | 2022 | 6405 | 0.320 |
Why?
|
| Biopsy | 4 | 2018 | 540 | 0.320 |
Why?
|
| Young Adult | 16 | 2022 | 5717 | 0.320 |
Why?
|
| Dust | 1 | 2008 | 9 | 0.320 |
Why?
|
| Arginine | 4 | 1997 | 102 | 0.320 |
Why?
|
| Fibroblasts | 3 | 2012 | 902 | 0.310 |
Why?
|
| Gene Frequency | 12 | 2020 | 207 | 0.310 |
Why?
|
| Gene Expression Profiling | 6 | 2020 | 498 | 0.310 |
Why?
|
| Complement Factor D | 2 | 2007 | 3 | 0.310 |
Why?
|
| Agriculture | 1 | 2008 | 54 | 0.310 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2007 | 22 | 0.300 |
Why?
|
| Peroxidase | 1 | 2007 | 40 | 0.300 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2007 | 46 | 0.290 |
Why?
|
| Disease Progression | 10 | 2020 | 1038 | 0.290 |
Why?
|
| src-Family Kinases | 3 | 2014 | 91 | 0.290 |
Why?
|
| Interferon-gamma | 7 | 2007 | 241 | 0.290 |
Why?
|
| Genes, MHC Class I | 1 | 2006 | 14 | 0.280 |
Why?
|
| Light | 1 | 2007 | 152 | 0.280 |
Why?
|
| Survival Rate | 4 | 2018 | 1056 | 0.280 |
Why?
|
| Genes, Immunoglobulin | 3 | 1997 | 56 | 0.280 |
Why?
|
| Vitamin D | 4 | 2016 | 516 | 0.280 |
Why?
|
| Trans-Activators | 2 | 2005 | 237 | 0.280 |
Why?
|
| Chromosome Mapping | 9 | 2013 | 188 | 0.280 |
Why?
|
| Retinal Degeneration | 1 | 2007 | 75 | 0.280 |
Why?
|
| Adjuvants, Immunologic | 2 | 2018 | 63 | 0.280 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2006 | 1 | 0.280 |
Why?
|
| Genetic Association Studies | 7 | 2018 | 103 | 0.270 |
Why?
|
| Immunophenotyping | 6 | 2014 | 110 | 0.270 |
Why?
|
| Pancreatitis, Chronic | 2 | 2019 | 168 | 0.270 |
Why?
|
| Escherichia coli | 12 | 2003 | 368 | 0.270 |
Why?
|
| Family | 3 | 2019 | 293 | 0.270 |
Why?
|
| Repressor Proteins | 1 | 2007 | 183 | 0.270 |
Why?
|
| Age Factors | 9 | 2020 | 1864 | 0.270 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 3 | 2012 | 12 | 0.260 |
Why?
|
| Lymphocyte Activation | 11 | 2012 | 397 | 0.260 |
Why?
|
| STAT4 Transcription Factor | 3 | 2018 | 12 | 0.260 |
Why?
|
| Cohort Studies | 12 | 2014 | 2358 | 0.260 |
Why?
|
| Transplantation, Homologous | 7 | 2018 | 242 | 0.260 |
Why?
|
| Genetic Variation | 5 | 2014 | 220 | 0.260 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2012 | 216 | 0.260 |
Why?
|
| Bone Marrow Cells | 5 | 2013 | 217 | 0.250 |
Why?
|
| Smoking | 4 | 2014 | 1452 | 0.250 |
Why?
|
| Sex Factors | 8 | 2020 | 1266 | 0.250 |
Why?
|
| Environmental Exposure | 3 | 2008 | 269 | 0.250 |
Why?
|
| Microfilament Proteins | 1 | 2005 | 102 | 0.250 |
Why?
|
| Antibody Formation | 7 | 2010 | 93 | 0.250 |
Why?
|
| Immunoglobulin Isotypes | 6 | 2006 | 28 | 0.250 |
Why?
|
| Genetic Linkage | 5 | 2018 | 90 | 0.250 |
Why?
|
| Quality of Life | 3 | 2017 | 1515 | 0.250 |
Why?
|
| Gene Deletion | 2 | 2011 | 235 | 0.250 |
Why?
|
| Cell Differentiation | 4 | 2014 | 1034 | 0.250 |
Why?
|
| Complement Inactivating Agents | 3 | 2011 | 56 | 0.240 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2004 | 38 | 0.240 |
Why?
|
| Camptothecin | 2 | 2021 | 39 | 0.240 |
Why?
|
| Health Status Disparities | 1 | 2008 | 326 | 0.240 |
Why?
|
| CD11b Antigen | 3 | 2009 | 47 | 0.240 |
Why?
|
| Immunoglobulin Light Chains | 3 | 2004 | 19 | 0.240 |
Why?
|
| Antibody-Producing Cells | 1 | 2004 | 5 | 0.240 |
Why?
|
| Complementarity Determining Regions | 2 | 2004 | 4 | 0.240 |
Why?
|
| Microsatellite Repeats | 4 | 2010 | 40 | 0.240 |
Why?
|
| Toll-Like Receptor 7 | 2 | 2014 | 17 | 0.230 |
Why?
|
| B-Lymphocyte Subsets | 2 | 2022 | 25 | 0.230 |
Why?
|
| Herpesvirus 4, Human | 2 | 2019 | 30 | 0.230 |
Why?
|
| Interleukin-2 | 3 | 2014 | 133 | 0.230 |
Why?
|
| Rheumatoid Factor | 6 | 2008 | 21 | 0.230 |
Why?
|
| Immune Tolerance | 2 | 2018 | 114 | 0.230 |
Why?
|
| Mice, Mutant Strains | 8 | 2010 | 166 | 0.230 |
Why?
|
| NF-kappa B | 5 | 2017 | 432 | 0.230 |
Why?
|
| Aged | 20 | 2022 | 14862 | 0.220 |
Why?
|
| Quantitative Trait Loci | 3 | 2018 | 35 | 0.220 |
Why?
|
| Organ Size | 7 | 2009 | 242 | 0.220 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2006 | 411 | 0.220 |
Why?
|
| Mice, Inbred Strains | 11 | 2008 | 181 | 0.220 |
Why?
|
| Retroperitoneal Fibrosis | 2 | 1996 | 5 | 0.220 |
Why?
|
| Immunoglobulin M | 9 | 2022 | 172 | 0.220 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 4 | 2012 | 95 | 0.220 |
Why?
|
| Hair Dyes | 2 | 2004 | 3 | 0.220 |
Why?
|
| Species Specificity | 6 | 2009 | 303 | 0.210 |
Why?
|
| Prolactin | 1 | 2002 | 61 | 0.210 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2022 | 24 | 0.210 |
Why?
|
| Staphylococcus aureus | 2 | 2022 | 175 | 0.200 |
Why?
|
| Interleukin-17 | 1 | 2022 | 62 | 0.200 |
Why?
|
| Severity of Illness Index | 5 | 2010 | 1851 | 0.200 |
Why?
|
| Receptors, Complement 3d | 2 | 2014 | 45 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2010 | 710 | 0.200 |
Why?
|
| E2F Transcription Factors | 1 | 2022 | 48 | 0.200 |
Why?
|
| Epistasis, Genetic | 4 | 2012 | 32 | 0.200 |
Why?
|
| Killer Cells, Natural | 5 | 2009 | 94 | 0.200 |
Why?
|
| Binding Sites | 5 | 2018 | 631 | 0.200 |
Why?
|
| Immunity, Mucosal | 2 | 2018 | 19 | 0.200 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2021 | 4 | 0.200 |
Why?
|
| Immune Complex Diseases | 1 | 2001 | 10 | 0.190 |
Why?
|
| Topotecan | 1 | 2021 | 17 | 0.190 |
Why?
|
| Bone Marrow Transplantation | 5 | 2018 | 149 | 0.190 |
Why?
|
| DNA Methylation | 1 | 2023 | 193 | 0.190 |
Why?
|
| CD3 Complex | 3 | 2015 | 35 | 0.190 |
Why?
|
| Amino Acid Sequence | 6 | 2004 | 1083 | 0.190 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 2 | 2012 | 9 | 0.190 |
Why?
|
| Alkanesulfonic Acids | 2 | 2014 | 54 | 0.190 |
Why?
|
| Scleroderma, Systemic | 2 | 2023 | 446 | 0.190 |
Why?
|
| Endothelium | 1 | 2020 | 98 | 0.180 |
Why?
|
| Fluorocarbons | 2 | 2014 | 82 | 0.180 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2002 | 234 | 0.180 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 101 | 0.180 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 100 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 68 | 0.180 |
Why?
|
| Pilot Projects | 4 | 2020 | 1342 | 0.180 |
Why?
|
| Phosphorous Acids | 1 | 2020 | 4 | 0.180 |
Why?
|
| Oseltamivir | 1 | 2020 | 6 | 0.180 |
Why?
|
| G(M3) Ganglioside | 1 | 2020 | 7 | 0.180 |
Why?
|
| Islets of Langerhans | 2 | 2017 | 87 | 0.180 |
Why?
|
| Abortion, Criminal | 1 | 2019 | 1 | 0.180 |
Why?
|
| Mice, Transgenic | 6 | 2018 | 1033 | 0.180 |
Why?
|
| Immunoglobulin Class Switching | 3 | 2009 | 12 | 0.180 |
Why?
|
| Lactosylceramides | 1 | 2020 | 27 | 0.180 |
Why?
|
| Transition to Adult Care | 1 | 2020 | 18 | 0.180 |
Why?
|
| Neuraminidase | 1 | 2020 | 36 | 0.170 |
Why?
|
| Mutation | 6 | 2016 | 1213 | 0.170 |
Why?
|
| fas Receptor | 1 | 2000 | 54 | 0.170 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2017 | 101 | 0.170 |
Why?
|
| History, 21st Century | 1 | 2020 | 127 | 0.170 |
Why?
|
| Sjogren's Syndrome | 2 | 2017 | 18 | 0.170 |
Why?
|
| Occludin | 1 | 2019 | 7 | 0.170 |
Why?
|
| Antigens, Viral | 1 | 2019 | 35 | 0.170 |
Why?
|
| Herpesviridae Infections | 1 | 2019 | 23 | 0.170 |
Why?
|
| Bacterial Translocation | 1 | 2019 | 27 | 0.170 |
Why?
|
| Intestinal Mucosa | 2 | 2019 | 219 | 0.170 |
Why?
|
| Choroidal Neovascularization | 2 | 2010 | 35 | 0.170 |
Why?
|
| Longitudinal Studies | 4 | 2016 | 1054 | 0.160 |
Why?
|
| Stem Cells | 2 | 2017 | 248 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2011 | 376 | 0.160 |
Why?
|
| HLA Antigens | 2 | 2017 | 82 | 0.160 |
Why?
|
| Major Histocompatibility Complex | 1 | 2018 | 34 | 0.160 |
Why?
|
| Health Services Research | 1 | 2020 | 209 | 0.160 |
Why?
|
| Thrombosis | 3 | 2014 | 218 | 0.160 |
Why?
|
| Bone Marrow | 3 | 2014 | 168 | 0.160 |
Why?
|
| Patient Participation | 1 | 2020 | 146 | 0.160 |
Why?
|
| Epigenesis, Genetic | 2 | 2018 | 163 | 0.160 |
Why?
|
| Macular Degeneration | 2 | 2010 | 75 | 0.160 |
Why?
|
| Antibodies, Viral | 1 | 2019 | 110 | 0.160 |
Why?
|
| Progesterone | 1 | 2019 | 115 | 0.160 |
Why?
|
| Blood Proteins | 2 | 2013 | 94 | 0.150 |
Why?
|
| Introns | 4 | 2018 | 68 | 0.150 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2015 | 12 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2010 | 199 | 0.150 |
Why?
|
| Genetic Load | 1 | 2017 | 4 | 0.150 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2017 | 25 | 0.150 |
Why?
|
| Cell Line | 5 | 2013 | 1752 | 0.150 |
Why?
|
| Cyclooxygenase 2 | 3 | 2010 | 160 | 0.150 |
Why?
|
| Receptors, IgG | 1 | 1998 | 94 | 0.150 |
Why?
|
| Premature Birth | 1 | 2019 | 150 | 0.150 |
Why?
|
| Drug Resistance | 1 | 2018 | 223 | 0.140 |
Why?
|
| Complement Activation | 3 | 2009 | 145 | 0.140 |
Why?
|
| Tissue Donors | 2 | 2019 | 195 | 0.140 |
Why?
|
| Bacterial Infections | 1 | 1998 | 163 | 0.140 |
Why?
|
| Prevalence | 6 | 2016 | 1619 | 0.140 |
Why?
|
| GATA Transcription Factors | 2 | 2007 | 7 | 0.140 |
Why?
|
| STAT Transcription Factors | 2 | 2007 | 13 | 0.140 |
Why?
|
| Cost of Illness | 2 | 2009 | 206 | 0.140 |
Why?
|
| Chromosomes, Human, X | 2 | 2016 | 24 | 0.140 |
Why?
|
| Macrophages, Peritoneal | 3 | 2003 | 67 | 0.140 |
Why?
|
| Georgia | 2 | 2019 | 161 | 0.140 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 1996 | 30 | 0.140 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2016 | 24 | 0.140 |
Why?
|
| Albuminuria | 4 | 2011 | 171 | 0.140 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 1 | 2016 | 3 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2016 | 24 | 0.140 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1996 | 37 | 0.140 |
Why?
|
| Antigens, CD | 4 | 2012 | 230 | 0.140 |
Why?
|
| Estradiol | 1 | 2017 | 176 | 0.140 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2016 | 9 | 0.140 |
Why?
|
| Acetylation | 1 | 2016 | 94 | 0.140 |
Why?
|
| omega-N-Methylarginine | 4 | 2004 | 14 | 0.140 |
Why?
|
| Crosses, Genetic | 5 | 2000 | 60 | 0.140 |
Why?
|
| North Carolina | 4 | 2005 | 224 | 0.140 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2014 | 114 | 0.130 |
Why?
|
| Adipose Tissue | 1 | 2017 | 221 | 0.130 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 1 | 2016 | 5 | 0.130 |
Why?
|
| Cell Cycle Proteins | 2 | 2009 | 230 | 0.130 |
Why?
|
| Ceramides | 1 | 2020 | 578 | 0.130 |
Why?
|
| Immunoblotting | 3 | 2010 | 254 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2016 | 74 | 0.130 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2013 | 7 | 0.130 |
Why?
|
| Protein Binding | 6 | 2016 | 1027 | 0.130 |
Why?
|
| DEET | 2 | 2009 | 5 | 0.130 |
Why?
|
| Endothelial Cells | 2 | 2016 | 384 | 0.130 |
Why?
|
| Indians, North American | 2 | 2012 | 64 | 0.130 |
Why?
|
| Insect Repellents | 2 | 2009 | 8 | 0.130 |
Why?
|
| CD4 Antigens | 3 | 2008 | 42 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2015 | 35 | 0.130 |
Why?
|
| Pancreatitis | 1 | 2017 | 279 | 0.130 |
Why?
|
| Neutrophils | 1 | 2016 | 204 | 0.130 |
Why?
|
| Aged, 80 and over | 7 | 2008 | 4848 | 0.130 |
Why?
|
| Leptin | 1 | 2015 | 80 | 0.130 |
Why?
|
| Skin | 3 | 2012 | 451 | 0.120 |
Why?
|
| Treatment Outcome | 7 | 2014 | 7029 | 0.120 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2014 | 13 | 0.120 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2014 | 23 | 0.120 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2015 | 65 | 0.120 |
Why?
|
| Carrier Proteins | 2 | 2016 | 597 | 0.120 |
Why?
|
| beta Karyopherins | 1 | 2014 | 4 | 0.120 |
Why?
|
| Cell-Derived Microparticles | 1 | 2014 | 5 | 0.120 |
Why?
|
| Antigens, Differentiation | 2 | 2005 | 49 | 0.120 |
Why?
|
| Maze Learning | 1 | 2014 | 138 | 0.120 |
Why?
|
| Caprylates | 1 | 2014 | 32 | 0.120 |
Why?
|
| Thromboxane B2 | 3 | 2011 | 108 | 0.120 |
Why?
|
| Binding Sites, Antibody | 3 | 2004 | 34 | 0.120 |
Why?
|
| Interleukin-12 | 2 | 2006 | 75 | 0.120 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 1994 | 10 | 0.120 |
Why?
|
| Complement Factor H | 2 | 2011 | 21 | 0.120 |
Why?
|
| Pregnancy | 5 | 2019 | 2334 | 0.120 |
Why?
|
| Mice, Congenic | 4 | 2007 | 13 | 0.120 |
Why?
|
| Phosphoproteins | 2 | 2011 | 202 | 0.120 |
Why?
|
| Interleukin-1 | 2 | 2004 | 86 | 0.120 |
Why?
|
| Thymus Gland | 4 | 2009 | 97 | 0.110 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2013 | 14 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2010 | 32 | 0.110 |
Why?
|
| OX40 Ligand | 1 | 2013 | 7 | 0.110 |
Why?
|
| Ligands | 1 | 2014 | 317 | 0.110 |
Why?
|
| Lupus Erythematosus, Discoid | 2 | 2011 | 6 | 0.110 |
Why?
|
| MicroRNAs | 2 | 2022 | 447 | 0.110 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2013 | 21 | 0.110 |
Why?
|
| NADH Dehydrogenase | 1 | 2013 | 13 | 0.110 |
Why?
|
| Glutathione Reductase | 1 | 2013 | 17 | 0.110 |
Why?
|
| Membrane Glycoproteins | 2 | 2014 | 370 | 0.110 |
Why?
|
| Electron Transport Complex I | 1 | 2013 | 20 | 0.110 |
Why?
|
| RNA, Small Cytoplasmic | 1 | 1993 | 1 | 0.110 |
Why?
|
| Hydrocarbons | 2 | 2004 | 12 | 0.110 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 1993 | 11 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2013 | 35 | 0.110 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2013 | 20 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2016 | 209 | 0.110 |
Why?
|
| Complement C1q | 2 | 2011 | 18 | 0.110 |
Why?
|
| Sequence Deletion | 2 | 2017 | 89 | 0.110 |
Why?
|
| Body Weight | 4 | 2009 | 554 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 2 | 2011 | 274 | 0.110 |
Why?
|
| Thiazoles | 3 | 2003 | 95 | 0.110 |
Why?
|
| Indians, South American | 1 | 2012 | 12 | 0.110 |
Why?
|
| Pyridostigmine Bromide | 2 | 2004 | 11 | 0.110 |
Why?
|
| Transplantation, Isogeneic | 1 | 2012 | 19 | 0.110 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 53 | 0.110 |
Why?
|
| Nephritis | 1 | 2012 | 37 | 0.110 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 1174 | 0.100 |
Why?
|
| Genetic Markers | 6 | 2012 | 144 | 0.100 |
Why?
|
| Guanosine | 1 | 2012 | 3 | 0.100 |
Why?
|
| Egg Proteins | 1 | 2012 | 15 | 0.100 |
Why?
|
| Genome, Human | 2 | 2013 | 62 | 0.100 |
Why?
|
| Ikaros Transcription Factor | 1 | 2012 | 26 | 0.100 |
Why?
|
| CpG Islands | 1 | 2012 | 51 | 0.100 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2012 | 14 | 0.100 |
Why?
|
| Macrophage Activation | 2 | 2003 | 75 | 0.100 |
Why?
|
| Age of Onset | 4 | 2017 | 188 | 0.100 |
Why?
|
| Time Factors | 5 | 2008 | 4655 | 0.100 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2012 | 22 | 0.100 |
Why?
|
| Molecular Motor Proteins | 1 | 2011 | 14 | 0.100 |
Why?
|
| Sierra Leone | 1 | 2011 | 5 | 0.100 |
Why?
|
| Jurkat Cells | 3 | 2020 | 59 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2014 | 282 | 0.100 |
Why?
|
| Myosin Heavy Chains | 1 | 2011 | 49 | 0.100 |
Why?
|
| Lysophospholipids | 2 | 2010 | 209 | 0.100 |
Why?
|
| Complement Pathway, Classical | 1 | 2011 | 22 | 0.100 |
Why?
|
| Social Problems | 1 | 2011 | 13 | 0.100 |
Why?
|
| Apolipoproteins | 1 | 2011 | 51 | 0.100 |
Why?
|
| Emigration and Immigration | 1 | 2011 | 33 | 0.100 |
Why?
|
| Heterozygote | 4 | 2014 | 174 | 0.100 |
Why?
|
| Logistic Models | 6 | 2017 | 1420 | 0.100 |
Why?
|
| Interferon-alpha | 1 | 2011 | 46 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2011 | 15 | 0.100 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 113 | 0.100 |
Why?
|
| HLA-DR Antigens | 2 | 2008 | 41 | 0.100 |
Why?
|
| Protein Phosphatase 2 | 1 | 2011 | 67 | 0.100 |
Why?
|
| Exodeoxyribonucleases | 1 | 2011 | 8 | 0.100 |
Why?
|
| Sphingosine | 2 | 2010 | 315 | 0.100 |
Why?
|
| Retinal Pigment Epithelium | 2 | 2010 | 145 | 0.100 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2010 | 9 | 0.090 |
Why?
|
| Phosphorylation | 5 | 2012 | 1200 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2017 | 2007 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 199 | 0.090 |
Why?
|
| Interleukins | 1 | 2011 | 79 | 0.090 |
Why?
|
| Mycophenolic Acid | 2 | 2014 | 62 | 0.090 |
Why?
|
| RNA, Small Interfering | 3 | 2020 | 434 | 0.090 |
Why?
|
| Electroretinography | 2 | 2009 | 122 | 0.090 |
Why?
|
| Environment | 1 | 2011 | 115 | 0.090 |
Why?
|
| Cryoglobulins | 2 | 2001 | 4 | 0.090 |
Why?
|
| Cross Reactions | 3 | 1996 | 57 | 0.090 |
Why?
|
| Cyclophosphamide | 2 | 2014 | 129 | 0.090 |
Why?
|
| Isoenzymes | 2 | 2004 | 308 | 0.090 |
Why?
|
| Arrestins | 1 | 2011 | 92 | 0.090 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 132 | 0.090 |
Why?
|
| Suppressor of Cytokine Signaling 3 Protein | 1 | 2010 | 12 | 0.090 |
Why?
|
| Cell Line, Transformed | 2 | 2012 | 100 | 0.090 |
Why?
|
| Foot Joints | 1 | 2010 | 6 | 0.090 |
Why?
|
| Blood Urea Nitrogen | 2 | 2008 | 65 | 0.090 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2010 | 12 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2012 | 250 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 2800 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2013 | 3705 | 0.090 |
Why?
|
| Immunoglobulin E | 1 | 2010 | 91 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 2279 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 3259 | 0.090 |
Why?
|
| Hypersensitivity | 1 | 2010 | 52 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 290 | 0.090 |
Why?
|
| Receptors, Antigen, B-Cell | 3 | 2022 | 89 | 0.090 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 2 | 2004 | 8 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2010 | 714 | 0.090 |
Why?
|
| Gene Knock-In Techniques | 2 | 2021 | 35 | 0.090 |
Why?
|
| Transcriptome | 2 | 2023 | 164 | 0.090 |
Why?
|
| Confidence Intervals | 3 | 2008 | 242 | 0.090 |
Why?
|
| Homozygote | 3 | 2022 | 119 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2010 | 141 | 0.090 |
Why?
|
| Ankle Joint | 1 | 2010 | 57 | 0.090 |
Why?
|
| Interleukin-21 Receptor alpha Subunit | 1 | 2009 | 1 | 0.090 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 122 | 0.090 |
Why?
|
| Hyaluronan Receptors | 1 | 2010 | 142 | 0.090 |
Why?
|
| Neural Pathways | 1 | 2011 | 324 | 0.090 |
Why?
|
| Nitric Oxide Donors | 2 | 2007 | 54 | 0.080 |
Why?
|
| Prognosis | 3 | 2010 | 2093 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2013 | 867 | 0.080 |
Why?
|
| Osteoclasts | 1 | 2010 | 132 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2007 | 320 | 0.080 |
Why?
|
| Sex Distribution | 2 | 2016 | 274 | 0.080 |
Why?
|
| Collagen | 1 | 2012 | 636 | 0.080 |
Why?
|
| Calcium | 1 | 2013 | 929 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2009 | 266 | 0.080 |
Why?
|
| Carpal Bones | 1 | 1988 | 7 | 0.080 |
Why?
|
| Alternative Splicing | 1 | 2009 | 93 | 0.080 |
Why?
|
| Wood | 1 | 2008 | 5 | 0.080 |
Why?
|
| Animal Husbandry | 1 | 2008 | 10 | 0.080 |
Why?
|
| Crops, Agricultural | 1 | 2008 | 10 | 0.080 |
Why?
|
| Caco-2 Cells | 2 | 2019 | 37 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2010 | 1046 | 0.080 |
Why?
|
| Paper | 1 | 2008 | 23 | 0.080 |
Why?
|
| I-kappa B Proteins | 3 | 2006 | 47 | 0.080 |
Why?
|
| Fatty Acid Desaturases | 1 | 1988 | 3 | 0.080 |
Why?
|
| Lymphoid Tissue | 1 | 2008 | 30 | 0.080 |
Why?
|
| Industry | 1 | 2008 | 28 | 0.080 |
Why?
|
| Riboflavin | 1 | 1988 | 15 | 0.080 |
Why?
|
| Dextran Sulfate | 1 | 2008 | 88 | 0.080 |
Why?
|
| Lysine | 1 | 2008 | 96 | 0.080 |
Why?
|
| Mitochondria | 1 | 2013 | 643 | 0.080 |
Why?
|
| Osteopontin | 1 | 2008 | 28 | 0.080 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 2 | 2008 | 15 | 0.080 |
Why?
|
| NIH 3T3 Cells | 2 | 2020 | 65 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2011 | 447 | 0.080 |
Why?
|
| Muscular Diseases | 1 | 1988 | 41 | 0.080 |
Why?
|
| Creatinine | 2 | 2010 | 243 | 0.080 |
Why?
|
| Elapid Venoms | 1 | 2007 | 5 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2008 | 880 | 0.080 |
Why?
|
| Mutagenesis, Insertional | 2 | 2017 | 24 | 0.080 |
Why?
|
| Chemokines | 2 | 2006 | 119 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 508 | 0.070 |
Why?
|
| CD55 Antigens | 1 | 2007 | 13 | 0.070 |
Why?
|
| Sequence Alignment | 2 | 2020 | 165 | 0.070 |
Why?
|
| Immunity, Cellular | 2 | 2004 | 80 | 0.070 |
Why?
|
| Sphingolipids | 1 | 2010 | 337 | 0.070 |
Why?
|
| Colitis | 1 | 2008 | 156 | 0.070 |
Why?
|
| Registries | 1 | 2010 | 733 | 0.070 |
Why?
|
| Administration, Oral | 4 | 2005 | 411 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 159 | 0.070 |
Why?
|
| Bayes Theorem | 3 | 2015 | 307 | 0.070 |
Why?
|
| Clonidine | 1 | 1987 | 66 | 0.070 |
Why?
|
| Recombination, Genetic | 1 | 2007 | 62 | 0.070 |
Why?
|
| Social Class | 1 | 2007 | 127 | 0.070 |
Why?
|
| Kidney Tubules | 1 | 2007 | 80 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2007 | 82 | 0.070 |
Why?
|
| Mice, Inbred C3H | 3 | 1996 | 134 | 0.070 |
Why?
|
| Immediate-Early Proteins | 2 | 1997 | 63 | 0.070 |
Why?
|
| Tight Junctions | 2 | 2019 | 25 | 0.070 |
Why?
|
| Persian Gulf Syndrome | 2 | 2009 | 27 | 0.070 |
Why?
|
| Random Allocation | 1 | 2007 | 442 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2008 | 3187 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2008 | 384 | 0.070 |
Why?
|
| Antibodies, Anticardiolipin | 2 | 2013 | 15 | 0.070 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2005 | 95 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2007 | 231 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 792 | 0.070 |
Why?
|
| Genome | 1 | 2006 | 54 | 0.070 |
Why?
|
| Obesity | 1 | 2013 | 1076 | 0.070 |
Why?
|
| Southeastern United States | 5 | 2004 | 281 | 0.060 |
Why?
|
| Complement C4 | 2 | 2010 | 15 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2007 | 211 | 0.060 |
Why?
|
| Immune System | 2 | 2006 | 63 | 0.060 |
Why?
|
| Models, Biological | 2 | 2010 | 981 | 0.060 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2005 | 24 | 0.060 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2005 | 29 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2005 | 115 | 0.060 |
Why?
|
| Fetal Death | 1 | 2005 | 49 | 0.060 |
Why?
|
| Seasons | 1 | 2005 | 129 | 0.060 |
Why?
|
| Lymphopenia | 1 | 2004 | 12 | 0.060 |
Why?
|
| PPAR delta | 1 | 2004 | 14 | 0.060 |
Why?
|
| Injections, Intraperitoneal | 1 | 2004 | 89 | 0.060 |
Why?
|
| Blood | 1 | 2004 | 40 | 0.060 |
Why?
|
| Health Status | 1 | 2007 | 429 | 0.060 |
Why?
|
| Lymphotoxin-alpha | 1 | 2004 | 9 | 0.060 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2004 | 1 | 0.060 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Light Chain | 1 | 2004 | 2 | 0.060 |
Why?
|
| Vaccination | 2 | 2022 | 189 | 0.060 |
Why?
|
| Immunoglobulins | 3 | 2000 | 97 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2005 | 291 | 0.060 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2004 | 77 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1995 | 231 | 0.060 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2004 | 11 | 0.060 |
Why?
|
| Multigene Family | 1 | 2004 | 93 | 0.060 |
Why?
|
| Models, Genetic | 2 | 2018 | 161 | 0.060 |
Why?
|
| Chromans | 1 | 2003 | 12 | 0.060 |
Why?
|
| Microscopy, Electron | 1 | 2004 | 351 | 0.060 |
Why?
|
| Gram-Positive Bacteria | 1 | 2003 | 23 | 0.060 |
Why?
|
| Mice, Inbred DBA | 2 | 2011 | 120 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2016 | 326 | 0.060 |
Why?
|
| Pedigree | 2 | 2016 | 159 | 0.060 |
Why?
|
| Joint Diseases | 1 | 2003 | 37 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 951 | 0.050 |
Why?
|
| Gram-Negative Bacteria | 1 | 2003 | 55 | 0.050 |
Why?
|
| Proteins | 2 | 1997 | 474 | 0.050 |
Why?
|
| Remission Induction | 3 | 2014 | 111 | 0.050 |
Why?
|
| Cell Division | 1 | 2004 | 541 | 0.050 |
Why?
|
| Exons | 3 | 2009 | 122 | 0.050 |
Why?
|
| Peptidoglycan | 1 | 2022 | 14 | 0.050 |
Why?
|
| Cell Wall | 1 | 2022 | 21 | 0.050 |
Why?
|
| CD11c Antigen | 1 | 2022 | 18 | 0.050 |
Why?
|
| Erythrocytes | 3 | 2008 | 137 | 0.050 |
Why?
|
| Menstruation | 1 | 2002 | 20 | 0.050 |
Why?
|
| Acetyltransferases | 1 | 2022 | 49 | 0.050 |
Why?
|
| Contraceptives, Oral | 1 | 2002 | 28 | 0.050 |
Why?
|
| Hormone Replacement Therapy | 1 | 2002 | 20 | 0.050 |
Why?
|
| Spermine | 1 | 2022 | 49 | 0.050 |
Why?
|
| Menopause | 1 | 2002 | 47 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2017 | 238 | 0.050 |
Why?
|
| Interferons | 1 | 2022 | 36 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 240 | 0.050 |
Why?
|
| Antibodies | 1 | 2003 | 241 | 0.050 |
Why?
|
| Silicon Dioxide | 1 | 2002 | 61 | 0.050 |
Why?
|
| Hemoglobins | 2 | 2004 | 120 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2008 | 2455 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2003 | 166 | 0.050 |
Why?
|
| Blood Sedimentation | 2 | 1999 | 16 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 1745 | 0.050 |
Why?
|
| Gene Targeting | 1 | 2002 | 58 | 0.050 |
Why?
|
| Gene Dosage | 2 | 2016 | 47 | 0.050 |
Why?
|
| Feces | 1 | 2022 | 88 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2003 | 175 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2005 | 204 | 0.050 |
Why?
|
| Africa | 1 | 2021 | 41 | 0.050 |
Why?
|
| Infant | 1 | 2008 | 2891 | 0.050 |
Why?
|
| Genetic Carrier Screening | 1 | 2001 | 25 | 0.050 |
Why?
|
| Osteonecrosis | 1 | 2001 | 20 | 0.050 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2001 | 58 | 0.050 |
Why?
|
| Epoprostenol | 1 | 2001 | 71 | 0.050 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2020 | 8 | 0.050 |
Why?
|
| Sp1 Transcription Factor | 1 | 2020 | 21 | 0.050 |
Why?
|
| Europe | 1 | 2021 | 196 | 0.050 |
Why?
|
| Immunoglobulin Allotypes | 1 | 2001 | 82 | 0.050 |
Why?
|
| United States | 5 | 2012 | 7367 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 2 | 2012 | 41 | 0.050 |
Why?
|
| 3' Untranslated Regions | 2 | 2013 | 56 | 0.050 |
Why?
|
| Antibodies, Bacterial | 2 | 1993 | 90 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2001 | 99 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2002 | 159 | 0.050 |
Why?
|
| Epidemiologic Methods | 2 | 2010 | 83 | 0.050 |
Why?
|
| Bacteria | 1 | 2022 | 193 | 0.050 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 2 | 2011 | 7 | 0.050 |
Why?
|
| Catalase | 1 | 2000 | 85 | 0.040 |
Why?
|
| Metagenomics | 1 | 2020 | 11 | 0.040 |
Why?
|
| Oklahoma | 2 | 2010 | 18 | 0.040 |
Why?
|
| Self Report | 1 | 2022 | 371 | 0.040 |
Why?
|
| Metagenome | 1 | 2020 | 17 | 0.040 |
Why?
|
| Reperfusion Injury | 1 | 2003 | 320 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2003 | 232 | 0.040 |
Why?
|
| Vasculitis | 1 | 2000 | 33 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2011 | 28 | 0.040 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2000 | 73 | 0.040 |
Why?
|
| Peroxisomes | 1 | 2000 | 48 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 170 | 0.040 |
Why?
|
| Liver | 3 | 2004 | 1118 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 1999 | 119 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1988 | 2223 | 0.040 |
Why?
|
| Rheumatology | 1 | 2019 | 46 | 0.040 |
Why?
|
| Permeability | 1 | 2019 | 131 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2014 | 138 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2001 | 328 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1989 | 2324 | 0.040 |
Why?
|
| Epitopes | 2 | 2008 | 146 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 649 | 0.040 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2018 | 5 | 0.040 |
Why?
|
| Transfection | 2 | 2010 | 782 | 0.040 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 13 | 0.040 |
Why?
|
| Autophagy | 1 | 2020 | 208 | 0.040 |
Why?
|
| Infusions, Intravenous | 3 | 2009 | 334 | 0.040 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2021 | 266 | 0.040 |
Why?
|
| Transplantation Chimera | 1 | 2018 | 10 | 0.040 |
Why?
|
| Solubility | 1 | 1998 | 134 | 0.040 |
Why?
|
| Lung | 1 | 2003 | 849 | 0.040 |
Why?
|
| HLA-DRB1 Chains | 2 | 2008 | 21 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 219 | 0.040 |
Why?
|
| Nonheme Iron Proteins | 1 | 1998 | 2 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 2008 | 18 | 0.040 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2018 | 21 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 56 | 0.040 |
Why?
|
| Femur Head Necrosis | 1 | 1997 | 7 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 78 | 0.040 |
Why?
|
| Peptides, Cyclic | 2 | 2008 | 35 | 0.040 |
Why?
|
| Tissue Survival | 1 | 2017 | 22 | 0.040 |
Why?
|
| Keratins | 1 | 2017 | 48 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2018 | 156 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2017 | 10 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2017 | 31 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 1997 | 137 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2017 | 147 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 58 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 138 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2011 | 954 | 0.040 |
Why?
|
| Cell Count | 2 | 2010 | 248 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 145 | 0.040 |
Why?
|
| DNA Primers | 2 | 2010 | 302 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2002 | 1330 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2014 | 186 | 0.040 |
Why?
|
| Cattle | 3 | 2000 | 475 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 110 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 286 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2017 | 129 | 0.030 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2016 | 6 | 0.030 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2016 | 21 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 45 | 0.030 |
Why?
|
| Receptors, Calcitriol | 1 | 2016 | 49 | 0.030 |
Why?
|
| Trisomy | 1 | 2016 | 47 | 0.030 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1996 | 42 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 19 | 0.030 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2016 | 58 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 144 | 0.030 |
Why?
|
| Hybridomas | 1 | 1995 | 25 | 0.030 |
Why?
|
| Cachexia | 1 | 1996 | 54 | 0.030 |
Why?
|
| Sarcoidosis | 1 | 2016 | 77 | 0.030 |
Why?
|
| Crithidia | 1 | 1995 | 1 | 0.030 |
Why?
|
| DNA, Protozoan | 1 | 1995 | 8 | 0.030 |
Why?
|
| Incidence | 2 | 1997 | 1603 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 1999 | 1465 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 52 | 0.030 |
Why?
|
| Phytohemagglutinins | 1 | 2014 | 16 | 0.030 |
Why?
|
| Retreatment | 1 | 2014 | 59 | 0.030 |
Why?
|
| CTLA-4 Antigen | 2 | 2005 | 45 | 0.030 |
Why?
|
| CD4-CD8 Ratio | 2 | 2004 | 5 | 0.030 |
Why?
|
| PPAR alpha | 1 | 2014 | 31 | 0.030 |
Why?
|
| Receptors, Complement 3b | 1 | 2014 | 35 | 0.030 |
Why?
|
| Insulin | 1 | 2017 | 619 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2017 | 631 | 0.030 |
Why?
|
| Models, Molecular | 1 | 1996 | 546 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2014 | 60 | 0.030 |
Why?
|
| NF-KappaB Inhibitor alpha | 2 | 2006 | 28 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 54 | 0.030 |
Why?
|
| Clone Cells | 1 | 1993 | 67 | 0.030 |
Why?
|
| Diet | 1 | 1997 | 514 | 0.030 |
Why?
|
| Immunoglobulin A | 2 | 2008 | 79 | 0.030 |
Why?
|
| Poly G | 1 | 1993 | 2 | 0.030 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2013 | 3 | 0.030 |
Why?
|
| Ku Autoantigen | 1 | 2013 | 5 | 0.030 |
Why?
|
| snRNP Core Proteins | 1 | 1993 | 5 | 0.030 |
Why?
|
| Polynucleotides | 1 | 1993 | 4 | 0.030 |
Why?
|
| Mice, Inbred CBA | 2 | 1992 | 107 | 0.030 |
Why?
|
| Micrococcus | 2 | 1992 | 4 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 1993 | 19 | 0.030 |
Why?
|
| Poly C | 1 | 1993 | 9 | 0.030 |
Why?
|
| Antigens, Nuclear | 1 | 2013 | 24 | 0.030 |
Why?
|
| Immunodiffusion | 1 | 2012 | 19 | 0.030 |
Why?
|
| B-Cell Activating Factor | 1 | 2012 | 12 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 2012 | 18 | 0.030 |
Why?
|
| Reference Values | 2 | 2006 | 579 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 5 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 1 | 2012 | 7 | 0.030 |
Why?
|
| Decorin | 1 | 2012 | 8 | 0.030 |
Why?
|
| Matrix Metalloproteinase 15 | 1 | 2012 | 5 | 0.030 |
Why?
|
| Lumican | 1 | 2012 | 8 | 0.030 |
Why?
|
| Cyclin E | 1 | 2012 | 19 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 122 | 0.030 |
Why?
|
| Keratan Sulfate | 1 | 2012 | 12 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2009 | 268 | 0.030 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2012 | 22 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2013 | 104 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 1992 | 34 | 0.030 |
Why?
|
| Focal Adhesions | 1 | 2012 | 25 | 0.030 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2012 | 36 | 0.030 |
Why?
|
| Morbidity | 1 | 2012 | 130 | 0.030 |
Why?
|
| Genetics, Population | 1 | 2012 | 21 | 0.030 |
Why?
|
| Actin Cytoskeleton | 1 | 2012 | 37 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2010 | 765 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2012 | 52 | 0.030 |
Why?
|
| Apolipoprotein L1 | 1 | 2011 | 16 | 0.030 |
Why?
|
| Knee Joint | 1 | 1992 | 115 | 0.020 |
Why?
|
| Acute Disease | 2 | 2010 | 658 | 0.020 |
Why?
|
| beta-Arrestin 1 | 1 | 2011 | 22 | 0.020 |
Why?
|
| Chickens | 2 | 1990 | 232 | 0.020 |
Why?
|
| beta-Arrestin 2 | 1 | 2011 | 29 | 0.020 |
Why?
|
| Oxidative Stress | 2 | 2010 | 718 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 694 | 0.020 |
Why?
|
| Immunoglobulin Gm Allotypes | 2 | 2004 | 103 | 0.020 |
Why?
|
| beta-Arrestins | 1 | 2011 | 80 | 0.020 |
Why?
|
| Cell Survival | 1 | 2014 | 901 | 0.020 |
Why?
|
| Oral Ulcer | 1 | 2011 | 22 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 208 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 247 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2011 | 43 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 2010 | 18 | 0.020 |
Why?
|
| GATA1 Transcription Factor | 1 | 2010 | 19 | 0.020 |
Why?
|
| Delphi Technique | 1 | 2010 | 62 | 0.020 |
Why?
|
| Platelet Activation | 1 | 2010 | 24 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2011 | 246 | 0.020 |
Why?
|
| Skin Physiological Phenomena | 1 | 2010 | 13 | 0.020 |
Why?
|
| HMGB1 Protein | 1 | 2010 | 23 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2010 | 45 | 0.020 |
Why?
|
| Platelet Count | 1 | 2010 | 100 | 0.020 |
Why?
|
| Internationality | 1 | 2010 | 74 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2003 | 791 | 0.020 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2010 | 42 | 0.020 |
Why?
|
| Myxovirus Resistance Proteins | 1 | 2010 | 4 | 0.020 |
Why?
|
| Lymph Nodes | 2 | 2007 | 258 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 307 | 0.020 |
Why?
|
| Thrombophlebitis | 1 | 1990 | 47 | 0.020 |
Why?
|
| Blood Coagulation Factors | 1 | 1990 | 44 | 0.020 |
Why?
|
| RNA | 1 | 1991 | 171 | 0.020 |
Why?
|
| Radiation Chimera | 1 | 2009 | 15 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2010 | 237 | 0.020 |
Why?
|
| Graft Survival | 1 | 2013 | 465 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 948 | 0.020 |
Why?
|
| Antigens | 1 | 2010 | 90 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2009 | 32 | 0.020 |
Why?
|
| Phospholipids | 1 | 1990 | 108 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 1753 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 180 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 322 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 306 | 0.020 |
Why?
|
| Receptors, Complement | 1 | 1990 | 58 | 0.020 |
Why?
|
| Mice, Inbred A | 1 | 1989 | 4 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 955 | 0.020 |
Why?
|
| Cytoskeletal Proteins | 1 | 2010 | 108 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1989 | 165 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2005 | 742 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2009 | 146 | 0.020 |
Why?
|
| Inactivation, Metabolic | 1 | 2009 | 28 | 0.020 |
Why?
|
| Choroid | 1 | 2009 | 22 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 546 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2012 | 493 | 0.020 |
Why?
|
| Arthritis, Gouty | 1 | 1988 | 2 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2010 | 231 | 0.020 |
Why?
|
| Nitroglycerin | 1 | 1988 | 20 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 1989 | 54 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2009 | 87 | 0.020 |
Why?
|
| Biological Availability | 1 | 2009 | 79 | 0.020 |
Why?
|
| Aging | 1 | 1995 | 911 | 0.020 |
Why?
|
| Interleukin-12 Subunit p35 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Angina, Unstable | 1 | 1988 | 50 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 1988 | 61 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 215 | 0.020 |
Why?
|
| Connective Tissue | 1 | 1988 | 61 | 0.020 |
Why?
|
| NFATC Transcription Factors | 1 | 2008 | 40 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 32 | 0.020 |
Why?
|
| Trinitrobenzenes | 1 | 2008 | 2 | 0.020 |
Why?
|
| Hemolytic Plaque Technique | 1 | 2008 | 4 | 0.020 |
Why?
|
| No-Observed-Adverse-Effect Level | 1 | 2008 | 5 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 2008 | 53 | 0.020 |
Why?
|
| Rheumatoid Nodule | 1 | 2008 | 3 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2008 | 20 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2010 | 483 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2008 | 56 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2010 | 215 | 0.020 |
Why?
|
| Muramidase | 1 | 2008 | 38 | 0.020 |
Why?
|
| Models, Animal | 1 | 2009 | 252 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2008 | 87 | 0.020 |
Why?
|
| Colon | 1 | 2008 | 168 | 0.020 |
Why?
|
| Musculoskeletal System | 1 | 2007 | 11 | 0.020 |
Why?
|
| Complement C3d | 1 | 2007 | 10 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2007 | 35 | 0.020 |
Why?
|
| IgA Deficiency | 1 | 2007 | 3 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 245 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 238 | 0.020 |
Why?
|
| Sweden | 1 | 2007 | 21 | 0.020 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2007 | 7 | 0.020 |
Why?
|
| Kinetics | 1 | 1989 | 1047 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 114 | 0.020 |
Why?
|
| Tristetraprolin | 2 | 1997 | 9 | 0.020 |
Why?
|
| Retina | 1 | 2009 | 252 | 0.020 |
Why?
|
| Radiography | 1 | 1988 | 572 | 0.020 |
Why?
|
| Pneumonia | 1 | 2008 | 110 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 392 | 0.020 |
Why?
|
| Citrulline | 1 | 2006 | 9 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 2007 | 173 | 0.020 |
Why?
|
| Dermatitis | 1 | 2007 | 28 | 0.020 |
Why?
|
| Chemokines, CX3C | 1 | 2006 | 3 | 0.020 |
Why?
|
| Chemokine CX3CL1 | 1 | 2006 | 6 | 0.020 |
Why?
|
| Lipocalins | 1 | 2006 | 7 | 0.020 |
Why?
|
| Acute-Phase Proteins | 1 | 2006 | 13 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2007 | 233 | 0.020 |
Why?
|
| Chemokine CXCL1 | 1 | 2006 | 21 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 16 | 0.020 |
Why?
|
| Income | 1 | 2007 | 167 | 0.020 |
Why?
|
| Lipocalin-2 | 1 | 2006 | 19 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2007 | 108 | 0.020 |
Why?
|
| Syndrome | 2 | 1997 | 255 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 1040 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2007 | 144 | 0.020 |
Why?
|
| Prednisone | 1 | 2005 | 104 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2006 | 146 | 0.020 |
Why?
|
| Hybridization, Genetic | 1 | 2005 | 9 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2005 | 10 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 331 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2005 | 260 | 0.020 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2005 | 15 | 0.020 |
Why?
|
| Luciferases | 1 | 2005 | 105 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1988 | 1140 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2005 | 191 | 0.020 |
Why?
|
| Erythrocyte Indices | 1 | 2004 | 9 | 0.020 |
Why?
|
| Erythrocyte Count | 1 | 2004 | 14 | 0.020 |
Why?
|
| Teratogens | 1 | 2004 | 11 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 1196 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 2 | 1997 | 57 | 0.020 |
Why?
|
| Hematocrit | 1 | 2004 | 70 | 0.020 |
Why?
|
| Mercury | 1 | 2004 | 34 | 0.020 |
Why?
|
| Serpins | 1 | 2006 | 205 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2007 | 470 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2004 | 89 | 0.010 |
Why?
|
| Concanavalin A | 1 | 2004 | 22 | 0.010 |
Why?
|
| HLA-DR2 Antigen | 1 | 2004 | 4 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2004 | 17 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2004 | 66 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 2004 | 24 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2007 | 415 | 0.010 |
Why?
|
| Granulocytes | 1 | 2003 | 22 | 0.010 |
Why?
|
| Solvents | 1 | 2004 | 109 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 365 | 0.010 |
Why?
|
| Rats | 2 | 2003 | 5300 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2005 | 222 | 0.010 |
Why?
|
| Hippocampus | 1 | 2007 | 471 | 0.010 |
Why?
|
| Polychlorinated Dibenzodioxins | 1 | 2004 | 38 | 0.010 |
Why?
|
| Peptides | 1 | 2006 | 455 | 0.010 |
Why?
|
| Complement C9 | 1 | 2003 | 5 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2004 | 150 | 0.010 |
Why?
|
| Environmental Monitoring | 1 | 2004 | 180 | 0.010 |
Why?
|
| Sunlight | 1 | 2003 | 59 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2003 | 130 | 0.010 |
Why?
|
| Photomicrography | 1 | 2001 | 14 | 0.010 |
Why?
|
| Educational Status | 1 | 2002 | 273 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2001 | 19 | 0.010 |
Why?
|
| Cyclopentanes | 1 | 2001 | 15 | 0.010 |
Why?
|
| Immunogenetics | 1 | 2001 | 8 | 0.010 |
Why?
|
| Molsidomine | 1 | 2000 | 5 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2001 | 289 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 150 | 0.010 |
Why?
|
| Femur | 1 | 2001 | 113 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 2000 | 23 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2001 | 147 | 0.010 |
Why?
|
| Rabbits | 1 | 2001 | 509 | 0.010 |
Why?
|
| Superoxide Dismutase | 1 | 2000 | 149 | 0.010 |
Why?
|
| Splenomegaly | 1 | 1999 | 13 | 0.010 |
Why?
|
| DNA Damage | 1 | 2000 | 190 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2001 | 284 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2010 | 7277 | 0.010 |
Why?
|
| Prothrombin Time | 1 | 1997 | 24 | 0.010 |
Why?
|
| Y Chromosome | 1 | 1997 | 5 | 0.010 |
Why?
|
| Hypertension | 1 | 1987 | 1535 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1997 | 201 | 0.010 |
Why?
|
| Brain | 1 | 2007 | 2176 | 0.010 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1996 | 13 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1996 | 44 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1996 | 94 | 0.010 |
Why?
|
| Fibrosis | 1 | 1996 | 371 | 0.010 |
Why?
|
| Lod Score | 1 | 1992 | 14 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 1992 | 18 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1992 | 25 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1992 | 85 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1992 | 189 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 492 | 0.010 |
Why?
|
| Salmon | 1 | 1990 | 9 | 0.010 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 1990 | 15 | 0.010 |
Why?
|
| Blood Coagulation Disorders | 1 | 1990 | 45 | 0.010 |
Why?
|
| Software | 1 | 1992 | 418 | 0.010 |
Why?
|